ClinicalTrials.gg

Program

VLA15

A development code. Also written as “VLA15 with Alum” and “VLA15 without Alum”.

In Pfizer's pipeline, Prophylactic vaccine – protein subunit (Lyme Disease). Its studies are mostly in Lyme Disease, led by Pfizer.

Furthest: phase 3, since Jul 5, 20228 company-led studies, 2 open or runningNext primary completion: Dec 4, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer82 open or runningphase 3since Jul 5, 2022Dec 21, 2016Dec 4, 2026phase 3 · NCT07500506
  • Named in Pfizer’s own pipeline as PF-07307405, phase 4, as of Nov 3, 2026 (source).

Also a collaborator on its studies: Valneva.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 21, 2016First study: phase 1 study in Lyme NeuroborreliosisFirst studyNCT03010228 · 179 enrolled · United States, Belgium
  2. Dec 6, 2018Phase 2 study in Lyme DiseaseNCT03769194 · 572 enrolled · United States, Belgium, Germany
  3. May 29, 2019Phase 2 study in Lyme DiseaseNCT03970733 · 246 enrolled · United States
  4. Mar 8, 2021Phase 2 study in Lyme DiseaseNCT04801420 · 625 enrolled · United States
  5. Jul 5, 2022Phase 3 study in Lyme DiseaseNCT05477524 · 12,546 enrolled · United States, Canada, Finland and more
  6. Nov 22, 2022Phase 3 study in Lyme DiseaseNCT05634811 · 3,547 enrolled · United States
  7. Oct 13, 2025Phase 3 study in Lyme DiseaseNCT07226882 · 207 enrolled · United States
  8. Mar 23, 2026Phase 3 study in Lyme DiseaseNCT07500506 · 1,712 planned · United States, Canada

Ahead

  1. Dec 4, 2026Primary completion: phase 3 study in Lyme DiseaseNCT07500506
  2. Jan 27, 2028Primary completion: phase 3 study in Lyme DiseaseNCT07226882

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Prophylactic vaccine – protein subunit (Lyme Disease)”the company's pipeline, read by Claude · source

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07500506Lyme Disease · United States, Canada3RecruitingDec 4, 20261,712
NCT07226882Lyme Disease · United States3Active, not recruitingJan 27, 2028207
NCT05634811Lyme Disease · United States3CompletedJul 21, 20253,547
NCT05477524Lyme Disease · United States, Canada, Finland and more3CompletedJan 7, 202612,546
NCT04801420Lyme Disease · United States2CompletedMar 25, 2022625
NCT03970733Lyme Disease · United States2CompletedApr 7, 2020246
NCT03769194Lyme Disease · United States, Belgium, Germany2CompletedDec 18, 2019572
NCT03010228Lyme Neuroborreliosis · United States, Belgium1CompletedSep 28, 2017179

How it is read

Names in the registry

  • “VLA15”, 7 entries
  • “VLA15 with Alum”, 1 entry
  • “VLA15 without Alum”, 1 entry

Codes read as this program: VLA15.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
VLA15 (Pfizer): development program | ClinicalTrials.gg